312 related articles for article (PubMed ID: 23528430)
1. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
[TBL] [Abstract][Full Text] [Related]
3. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
[TBL] [Abstract][Full Text] [Related]
4. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
Ausch C; Buxhofer-Ausch V; Oberkanins C; Holzer B; Minai-Pour M; Jahn S; Dandachi N; Zeillinger R; Kriegshäuser G
J Mol Diagn; 2009 Nov; 11(6):508-13. PubMed ID: 19797612
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
[TBL] [Abstract][Full Text] [Related]
7. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K;
Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.
Solassol J; Ramos J; Crapez E; Saifi M; Mangé A; Vianès E; Lamy PJ; Costes V; Maudelonde T
Int J Mol Sci; 2011; 12(5):3191-204. PubMed ID: 21686179
[TBL] [Abstract][Full Text] [Related]
9. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
10. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
[TBL] [Abstract][Full Text] [Related]
11. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
[TBL] [Abstract][Full Text] [Related]
12. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
13. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
Dono M; Massucco C; Chiara S; Sonaglio C; Mora M; Truini A; Cerruti G; Zoppoli G; Ballestrero A; Truini M; Ferrarini M; Zupo S
Mol Med; 2013 Feb; 18(1):1519-26. PubMed ID: 23255073
[TBL] [Abstract][Full Text] [Related]
14. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
15. Study of KRAS new predictive marker in a clinical laboratory.
Bando I; Cillero L; Sanz-Ortega J; Llovet P; Pescador P; Ferrer M; de la Hoya M; Sastre J; García ED; Caldés T
Clin Transl Oncol; 2012 Dec; 14(12):937-42. PubMed ID: 22865324
[TBL] [Abstract][Full Text] [Related]
16. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
[TBL] [Abstract][Full Text] [Related]
17. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
[TBL] [Abstract][Full Text] [Related]
18. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
20. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
